全球大規模分子藥物研發外包市場規模、佔有率、趨勢及成長分析報告（2026-2034年）

全球大分子藥物研發外包市場預計將從2025年的35億美元成長至2034年的81.3億美元，2026年至2034年的複合年成長率（CAGR）為9.82%。隨著製藥和生物技術公司擴大將藥物研發活動外包給專業服務供應商，該市場正在快速擴張。大分子藥物研發包括單株抗體、重組蛋白、疫苗和細胞療法等生技藥品的開發。生技藥品開發的複雜性以及對先進科學專業知識的需求，促使企業與合約研究組織（CRO）建立合作關係。對創新生物療法日益成長的需求，為外包服務提供者創造了巨大的成長機會。

慢性病盛行率的上升和生物製藥研發投入的增加是推動市場擴張的主要因素。外包使製藥公司能夠降低營運成本、縮短研發週期並利用尖端研究技術。不斷擴充的生物製藥和生物相似藥研發管線進一步增加了對專業藥物發現服務的需求。此外，蛋白質工程、抗體開發和生物資訊學的進步提高了研究效率和成功率，從而促進了市場成長。

隨著生物製藥在全球藥物研發領域的佔有率持續成長，市場前景依然強勁。腫瘤學、免疫學和罕見疾病領域的研究活動不斷增加，預計將進一步刺激藥物研發外包服務的需求。生物技術公司與合約研究組織（CRO）之間合作的加強預計將進一步加劇市場動態。隨著生物製藥領域創新步伐的加快，聚合物藥物研發外包市場預計將迎來顯著的長期成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含多個關鍵組成部分，旨在幫助您全面了解市場環境。

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的關鍵促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。本部分深入分析了競爭趨勢以及主要參與者所採取的策略，提供了寶貴的見解。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：這包括對主要地理區域的市場表現進行全面檢驗，確定高成長地區和區域趨勢，以更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新的投資機會。本部分重點在於潛在的成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，可根據客戶需求進行調整。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，以更有效地支援策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球大規模分子藥物研發外包市場：依工作流程分類

• 市場分析、洞察與預測
• 目標識別和篩檢
• 目標檢驗和功能資訊學
• 先導化合物的篩選與最佳化
• 臨床前開發
• 其他

第5章 全球大規模分子藥物研發外包市場：依服務類型分類

• 市場分析、洞察與預測
• 化學服務
• 生物服務

第6章：全球大規模分子藥物研發外包市場：依治療領域分類

• 市場分析、洞察與預測
• 呼吸系統
• 疼痛與麻醉
• 腫瘤學
• 眼科
• 血液學
• 心血管系統
• 內分泌
• 消化器官系統
• 免疫調節
• 感染疾病物
• 中樞神經系統
• 皮膚科
• 泌尿生殖系統

第7章：全球大規模分子藥物研發外包市場：依最終用途分類

• 市場分析、洞察與預測
• 製藥和生物技術公司
• 學術機構

第8章 全球大規模分子藥物研發外包市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和分銷通路合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Evotec SE
  • Charles River Laboratories InternationalInc
  • WuXi AppTec Co.Ltd
  • Laboratory Corporation Of America Holdings PPDInc
  • Merck & Co.Inc
  • GenScript BIoTech Corporation
  • Jubilant Biosys Limited
  • Pharmaron Beijing Co.Ltd
  • Syngene International Limited
  • Dalton Pharma Services
  • Domainex Ltd
  • Eurofins Scientific SE
  • QIAGEN NV
  • TCG Lifesciences Pvt. Ltd

The global large molecule drug discovery outsourcing market size is expected to reach USD 8.13 Billion in 2034 from USD 3.50 Billion in 2025, growing at a CAGR of 9.82 during 2026-2034.This market is growing rapidly as pharmaceutical and biotechnology companies increasingly outsource drug discovery activities to specialized service providers. Large molecule drug discovery involves the development of biologics such as monoclonal antibodies, recombinant proteins, vaccines, and cell-based therapies. The complexity of biologic drug development and the need for advanced scientific expertise are encouraging companies to partner with contract research organizations. Growing demand for innovative biologic therapies is creating significant growth opportunities for outsourcing providers.

The rising prevalence of chronic diseases and increasing investments in biologics research are major factors driving market expansion. Outsourcing allows pharmaceutical companies to reduce operational costs, accelerate development timelines, and access advanced research technologies. The growing pipeline of biologic drugs and biosimilars is further increasing demand for specialized discovery services. In addition, advancements in protein engineering, antibody development, and bioinformatics are supporting market growth by improving research efficiency and success rates.

Future growth prospects remain strong as biologics continue to account for a larger share of global pharmaceutical development. Expanding research activities in oncology, immunology, and rare diseases will create additional demand for outsourced discovery services. Increasing collaboration between biotechnology firms and contract research organizations is expected to strengthen market dynamics. As innovation in biologics accelerates, the large molecule drug discovery outsourcing market is poised for significant long-term growth.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Workflow

• Target Identification & Screening
• Target Validation & Functional Informatics
• Lead Identification & Candidate Optimization
• Preclinical Development
• Others

By Service

• Chemistry Services
• Biology Services

By Therapeutic Area

• Respiratory System
• Pain and Anesthesia
• Oncology
• Ophthalmology
• Hematology
• Cardiovascular
• Endocrine
• Gastrointestinal
• Immunomodulation
• Anti-infective
• Central Nervous System
• Dermatology
• Genitourinary System

By End-Use

• Pharmaceutical & Biotechnology Companies
• Academic Institutes

COMPANIES PROFILED

• Evotec SE, Charles River Laboratories International, Inc., WuXi AppTec Co., Ltd., Laboratory Corporation of America Holdings PPD, Inc., Merck & Co., Inc., GenScript Biotech Corporation, Jubilant Biosys Limited, Pharmaron Beijing Co., Ltd., Syngene International Limited, Dalton Pharma Services, Domainex Ltd., Eurofins Scientific SE, QIAGEN N.V., TCG Lifesciences Pvt. Ltd.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL LARGE MOLECULE DRUG DISCOVERY OUTSOURCING MARKET: BY WORKFLOW 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Workflow
• 4.2. Target Identification & Screening Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Target Validation & Functional Informatics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Lead Identification & Candidate Optimization Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Preclinical Development Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL LARGE MOLECULE DRUG DISCOVERY OUTSOURCING MARKET: BY SERVICE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Service
• 5.2. Chemistry Services Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Biology Services Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL LARGE MOLECULE DRUG DISCOVERY OUTSOURCING MARKET: BY THERAPEUTIC AREA 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Therapeutic Area
• 6.2. Respiratory System Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Pain and Anesthesia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Ophthalmology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Hematology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.8. Endocrine Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.9. Gastrointestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.10. Immunomodulation Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.11. Anti-infective Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.12. Central Nervous System Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.13. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.14. Genitourinary System Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL LARGE MOLECULE DRUG DISCOVERY OUTSOURCING MARKET: BY END-USE 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast End-use
• 7.2. Pharmaceutical & Biotechnology Companies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Academic Institutes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL LARGE MOLECULE DRUG DISCOVERY OUTSOURCING MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Workflow
  • 8.2.2 By Service
  • 8.2.3 By Therapeutic Area
  • 8.2.4 By End-use
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Workflow
  • 8.3.2 By Service
  • 8.3.3 By Therapeutic Area
  • 8.3.4 By End-use
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Workflow
  • 8.4.2 By Service
  • 8.4.3 By Therapeutic Area
  • 8.4.4 By End-use
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Workflow
  • 8.5.2 By Service
  • 8.5.3 By Therapeutic Area
  • 8.5.4 By End-use
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Workflow
  • 8.6.2 By Service
  • 8.6.3 By Therapeutic Area
  • 8.6.4 By End-use
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL LARGE MOLECULE DRUG DISCOVERY OUTSOURCING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Evotec SE
  • 10.2.2 Charles River Laboratories InternationalInc
  • 10.2.3 WuXi AppTec Co.Ltd
  • 10.2.4 Laboratory Corporation Of America Holdings PPDInc
  • 10.2.5 Merck & Co.Inc
  • 10.2.6 GenScript Biotech Corporation
  • 10.2.7 Jubilant Biosys Limited
  • 10.2.8 Pharmaron Beijing Co.Ltd
  • 10.2.9 Syngene International Limited
  • 10.2.10 Dalton Pharma Services
  • 10.2.11 Domainex Ltd
  • 10.2.12 Eurofins Scientific SE
  • 10.2.13 QIAGEN N.V
  • 10.2.14 TCG Lifesciences Pvt. Ltd